BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics

• Status: Completed
• Trial end date: 2019-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary objectives of this study are to investigate

• the safety and tolerability of increasing single oral doses of BAY 1830839 versus placebo under fasted conditions

• the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted conditions

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Body mass index (BMI) : ≥18.5 and ≤30 kg/m*2

Exclusion Criteria:

• Relevant diseases within the last 4 weeks prior to the first study drug administration

• Febrile illness within 4 weeks before the first study drug administration

• Known hypersensitivity to the study drugs or components of the preparations

• Clinically relevant findings in the physical examination